a study to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab in participants with moderately to severely active ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: the purpose of this study is to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab treatment in participants with moderately to severely active ulcerative colitis (uc).

the study drug, golimumab, belongs to a group of medicines known as tumor necrosis factor (tnf) inhibitors and is approved in the united states, european union, and canada for treatment of uc. studies have shown that people respond differently to treatment with tnf inhibitors and furthermore, some people may not actually respond to treatment. tests which could predict the likelihood of response to golimumab prior to treatment would be of benefit to people with uc. this is an open label (physicians and participants know the identity of the assigned treatment), multicenter study to evaluate the accuracy of a genetic test (a subset of the length-109 probe set panel) in predicting response to golimumab treatment in patients with moderately to severely active uc. the study will consist of a screening phase, an open label treatment phase (week 0 to week 50), and a follow-up visit at week 58. a subset of the length-109 probe set panel will be tested on samples obtained from colonic biopsies taken prior to treatment with golimumab for all participants at screening. all participants enrolled in the study will receive subcutaneous golimumab from week 0 to week 50; at the discretion of the investigator, participants will be given the option to self-administer golimumab from week 6 onwards. blood and fecal samples will be taken at various time points during the study; colonic biopsies will be taken at screening, week 6, and week 30; and endoscopies will be performed at week 0, week 6, and week 30. the study duration for each participant is expected to be approximately 58 weeks. participant safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * must have the following: a clinical diagnosis of moderately to severely active ulcerative colitis (uc), defined as a baseline mayo score of 6 to 12 (inclusive), for at least 3 months prior to screening; and a screening endoscopy with a \> = 2 endoscopy sub score of the mayo score as determined by a central reading of the video endoscopy * prior or current medication for uc must be as per protocol * prior to the screening endoscopy or the earliest entry in the mayo diary card (whichever of these 2 events comes first) the following conditions must be met: per protocol requirements for treatment with 6-mercaptopurine, azathioprine, or methotrexate; per protocol requirements for treatment with oral 5-aminosalicylate or oral corticosteroids; treatment must have been discontinued for at least 2 weeks for rectal corticosteroids, rectal 5-aminosalicylate compounds, parenteral corticosteroids, total parenteral nutrition, pentoxifylline, thalidomide or related agents, and antibiotics for the treatment of uc; and treatment with 6-thioguanine must have been discontinued for at least 4 weeks * must have had a colonoscopy as per the time frame described in the protocol for the following: extensive colitis for \> = 8 years; disease limited to the left side of the colon for \> = 10 years; participants \> = 45 years of age to assess for the presence of adenomatous polyps * must meet the tuberculosis and hepatitis b virus screening criteria as defined in the protocol exclusion criteria: * the presence of any of the following: severe extensive colitis; uc limited to the rectum only or to \<20 cm of the colon; a stoma; a fistula (or history of a fistula); symptomatic colonic or small bowel obstruction; adenomatous colonic polyps (or history of adenomatous colonic polyps); or indeterminate colitis or clinical findings suggestive of crohn's disease * history of extensive colonic resection (eg, less than 30 cm of colon remaining) or colonic mucosal dysplasia; requires (or has required within the 2 months prior to screening) surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, intra abdominal or pancreatic abscess requiring surgical drainage * have received the following concomitant or previous medical therapies: biologic therapy targeted at tumor necrosis factor alpha (eg, infliximab, adalimumab, golimumab, etanercept, certolizumab); natalizumab within 12 months of first golimumab administration; agents that deplete b- or t-cells (eg, rituximab, alemtuzumab, or visilizumab) within 12 months of first golimumab administration, or continue to manifest depletion of b- or t-cells more than 12 months after completion of therapy with lymphocyte depleting agents; cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks prior to first administration of golimumab; vedolizumab within 8 weeks prior to first golimumab administration; apheresis (ie, adacolumn apheresis) within 2 weeks prior to first administration of golimumab; any investigational drug within 4 weeks prior to first administration of golimumab or within 5 half-lives of the investigational agent, whichever is longer; or oral corticosteroids at a dose of greater than 40 mg of prednisone or its equivalent per day * have received, or are expected to receive, any live viral or bacterial vaccination within 8 weeks (or longer as indicated in the package insert of the relevant vaccine) prior to the first administration of golimumab or have had bacille calmette-guerin (bcg) vaccination within 12 months of screening * history of, or currently active illness, considered to be clinically significant by the investigator or any other illness that the investigator considers should exclude the participant from the study or that could interfere with the interpretation of the study results

Keywords: colitis, ulcerative golimumab cnto148 simponi length-109 probe set panel